MARKET

AUPH

AUPH

Aurinia Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.60
-0.03
-0.24%
Opening 13:50 06/17 EDT
OPEN
12.60
PREV CLOSE
12.63
HIGH
12.90
LOW
12.45
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
20.50
52 WEEK LOW
9.72
MARKET CAP
1.61B
P/E (TTM)
-14.5379
1D
5D
1M
3M
1Y
5Y
BRIEF-Aurinia Announces Addition Of Brinda Balakrishnan To Board Of Directors
reuters.com · 3d ago
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
VICTORIA, British Columbia, Jun 14, 2021--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021. ...
Business Wire · 3d ago
Aurinia Announces Results of the 2021 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") is pleased to announce that the eight incumbent directors of the Company were elected at the Company's annual general meeting (the "Meeting") held on June 7, 2021.
Business Wire · 06/07 23:05
BRIEF-Aurinia Announces Additional Analysis Of Its Aurora 1 Phase 3 Study Data Presented At Era-Edta 2021 Congress
reuters.com · 06/07 11:31
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
- New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of
New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of · 06/07 11:05
Unusual Options Activity Insight: Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (NASDAQ:AUPH) shares experienced unusual options activity on Thursday. The stock price moved down to $13.6 following the option alert.
Benzinga · 06/03 15:26
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 06/02 12:20
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Benzinga · 05/31 15:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AUPH. Analyze the recent business situations of Aurinia Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AUPH stock price target is 27.60 with a high estimate of 35.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 56.66M
% Owned: 44.21%
Shares Outstanding: 128.16M
TypeInstitutionsShares
Increased
51
7.44M
New
44
3.27M
Decreased
47
13.08M
Sold Out
19
3.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.19%
Pharmaceuticals & Medical Research
-0.09%
Key Executives
Chairman/Independent Director
George Milne
President/Chief Executive Officer/Director
Peter Greenleaf
Chief Financial Officer
Dennis Bourgeault
Chief Operating Officer
Michael Martin
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Stephen Robertson
Executive Vice President
Maxwell Donley
Executive Vice President
Robert Huizinga
Senior Vice President/IR Contact Officer
Glenn Schulman
Chief Marketing Officer
Neil Solomons
Vice President/Director of Sales
Fran Lynch
Vice President/Director of Marketing
Chris Hays
Vice President
Cara Felish
Vice President
Tim Hermes
Other
Max Colao
Director
Daniel Billen
Director
R. Hector MacKay-Dunn
Independent Director
Joseph Hagan
Independent Director
Michael Hayden
Independent Director
David Jayne
Independent Director
Jill Leversage
Independent Director
Timothy Walbert
No Data
About AUPH
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.